Truist Financial Reiterates Hold Rating for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH)‘s stock had its “hold” rating reaffirmed by research analysts at Truist Financial in a research report issued on Monday,Benzinga reports. They currently have a $113.00 price target on the medical equipment provider’s stock, down from their previous price target of $118.00. Truist Financial’s target price would indicate a potential upside of 12.11% from the stock’s previous close.

Several other equities research analysts also recently weighed in on ZBH. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday. Royal Bank of Canada reduced their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, Oppenheimer cut their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Down 0.1 %

ZBH stock opened at $100.79 on Monday. Zimmer Biomet has a one year low of $99.93 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. The firm has a market cap of $20.07 billion, a PE ratio of 22.65, a PEG ratio of 1.83 and a beta of 1.02. The firm’s 50 day moving average price is $107.34 and its 200-day moving average price is $108.07.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the business posted $2.20 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet will post 8.25 EPS for the current year.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors have recently modified their holdings of ZBH. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet during the third quarter worth about $28,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the 3rd quarter worth about $35,000. Finally, Kentucky Trust Co purchased a new stake in Zimmer Biomet in the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.